ADRENALIN (epinephrine) by Pfizer is adrenergic alpha-agonists [moa]. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ADRENALIN (epinephrine) is a small-molecule alpha-adrenergic agonist administered via intramuscular, intravenous, or subcutaneous injection in solution form. It is the first-line emergency treatment for anaphylaxis and severe allergic reactions, working by stimulating adrenergic receptors to rapidly reverse symptoms. The drug has been approved since 2012 and remains a critical, life-saving intervention in acute care settings.
Peak-stage product with stable but modest Part D claims indicates mature market with limited growth opportunity and smaller brand team focus.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Worked on ADRENALIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ADRENALIN offers career stability in a mature, mission-critical product with no competitive threats and strong patent protection through 2035. However, limited growth trajectory and zero linked job openings suggest smaller team size and modest expansion opportunities; roles focus on maintenance and operational excellence rather than innovation or launch activities.